

Published in final edited form as:

Cancer Cell. 2008 June ; 13(6): 529–541. doi:10.1016/j.ccr.2008.04.019.

***DACT3* is an epigenetic regulator of Wnt/ β -catenin signaling in colorectal cancer and is a therapeutic target of histone modifications**

Xia Jiang^{1,4}, Jing Tan^{1,4}, Jingsong Li¹, Saul Kivimäe², Xiaojing Yang¹, Li Zhuang¹, Puay Leng Lee¹, Mark TW. Chan¹, Lawrence Stanton³, Edison T. Liu¹, Benjamin N.R. Cheyette², and Qiang Yu^{1*}

¹*Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore.*

²*Department of Psychiatry, Graduate Programs in Developmental Biology and Neuroscience, University of California, San Francisco.*

³*Stem Cell and Developmental Biology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology and Research), Biopolis, Singapore.*

Summary

Genetic and epigenetic defects in Wnt/ β -catenin signaling play important roles in colorectal cancer progression. Here we identify *DACT3*, a member of the DACT (Dpr/Frodo) gene family, as a negative regulator of Wnt/ β -catenin signaling that is transcriptionally repressed in colorectal cancer. Unlike other Wnt signaling inhibitors that are silenced by DNA methylation, *DACT3* repression is associated with bivalent histone modifications. Remarkably, *DACT3* expression can be robustly de-repressed by a pharmacological combination that simultaneously targets both histone methylation and deacetylation, leading to strong inhibition of Dishevelled (Dvl)-mediated Wnt/ β -catenin signaling and massive apoptosis of colorectal cancer cells. Our study identifies *DACT3* as an important regulator of Wnt/ β -catenin signaling in colorectal cancer and suggests a potential strategy for therapeutic control of Wnt/ β -catenin signaling in colorectal cancer.

Significance

Wnt/ β -catenin signaling is one of most frequently deregulated pathways in colorectal cancer and is thus an important therapeutic target. Our study identifies *DACT3* as a negative regulator of Wnt/ β -catenin signaling that is epigenetically repressed in colorectal cancer. Repression of *DACT3* in colon cancer does not require DNA methylation but instead involves bivalent histone modifications. Of potential clinical importance, we identify a pharmacological approach that interferes with this epigenetic process and robustly induces *DACT3* expression, leading to inhibition of Wnt/ β -catenin signaling and dramatic apoptosis of colon cancer cells. This work identifies an epigenetic component of Wnt/ β -catenin regulation in colorectal cancer, and

*Correspondence to: Dr. Qiang Yu, Group Leader and Principal Investigator, Cancer Biology and Pharmacology, Genome Institute of Singapore, Email: yuq@gis.a-star.edu.sg, Fax: 65-6478-9003.

⁴These authors contributed equally to this work.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

thereby opens an important avenue for pharmacological perturbation of this important cancer pathway.

Introduction

Aberrant activation of Wnt/ β -catenin signaling is a major driving force in colon cancer (Kinzler and Vogelstein, 1996; Su et al., 1992; van de Wetering et al., 2002). Mutations in Wnt/ β -catenin pathway components including APC, Axin, and β -catenin itself are well-established causes of aberrant signaling activation leading to cancer (Lammi et al., 2004; Liu et al., 2000; Morin et al., 1997; Su et al., 1992). These genetic defects share in common that they result in the accumulation of β -catenin in the nucleus. Nuclear β -catenin interacts with members of the TCF/LEF transcription co-factor family to activate downstream target genes such as Cyclin D1 and Myc that can lead to cell transformation (He et al., 1998; Morin et al., 1997; Tetsu and McCormick, 1999; van de Wetering et al., 2002). The fact that blockade of Wnt/ β -catenin signaling in colon cancer cells induces apoptosis or growth inhibition both *in vitro* and *in vivo* (Fujii et al., 2007; He et al., 2005; Kwong et al., 2002) has propelled intensive efforts to develop therapeutic strategies that target this pathway (Barker and Clevers, 2006; Lepourcelet et al., 2004; Li et al., 2002).

In addition to genetic mutations in Wnt/ β -catenin pathway components, epigenetic events can also contribute to abnormal activation of this signaling pathway in cancer cells. For example, promoter methylation leading to transcriptional silencing of extracellular Wnt inhibitors, such as Secreted Frizzled-Related Proteins (SFRPs), Wnt Inhibitory Factor-1 (WIF-1), and DICKKOPF-1 (DKK-1), have been reported in human colorectal cancer cells (Aguilera et al., 2006; He et al., 2005; Morin et al., 1997; Suzuki et al., 2002). Conversely, restoration of Wnt inhibitor expression such as SFRP1/2 results in inhibition of Wnt/ β -catenin signaling and apoptosis of colorectal cancer cells even in the presence of downstream APC or β -catenin mutations (Baylin and Ohm, 2006; Suzuki et al., 2004). These findings suggest that epigenetic silencing of upstream Wnt inhibitor genes contributes to transformation through the amplification of aberrant signaling that may be initiated by genetic mutations (Baylin and Ohm, 2006; Suzuki et al., 2004). Consequently, epigenetic regulation of the Wnt/ β -catenin pathway has emerged as a potential therapeutic target in human cancer, though previously published efforts in this area have mainly focused on direct interference with TCF/ β -catenin-mediated transcriptional activation in cancer cells (Barker and Clevers, 2006; Lepourcelet et al., 2004).

The identification of new epigenetic regulators of Wnt/ β -catenin signaling may pave the way to developing innovative therapeutic strategies. Members of the DACT (Dpr/Frodo) gene family have been shown to modulate Wnt/ β -catenin signaling by interacting with Dishevelled (Dvl) (Cheyette et al., 2002), a central component of Wnt signaling (Bilic et al., 2007; Logan and Nusse, 2004). DACT1 and DACT2 antagonize Wnt signaling in some biological contexts, activate it in others, and may also play roles in TGF- β /Nodal signaling (Gloy et al., 2002; Hikasa and Sokol, 2004; Su et al., 2007; Zhang et al., 2006; Zhang et al., 2004). A third DACT family member, DACT3, has been described in both mouse and human (Fisher et al., 2006). However, up to now the signaling function of DACT3 has not been studied in any organism and nothing is known about its relevance to oncogenesis.

Results

***DACT3* expression is repressed in colorectal cancer independently of promoter methylation**

To characterize epigenetic effectors of Wnt/ β -catenin signaling in colorectal cancer, we initially focused on 14 representative Wnt signaling inhibitors, including members of the *SFRP*, *WIF1*, *DKK*, and *DACT* gene families, some of which have previously been shown to be transcriptionally inactivated or repressed in various human cancers (Aguilera et al., 2006;

He et al., 2005; Suzuki et al., 2002; Suzuki et al., 2004). We determined gene expression in 24 human colorectal tumors versus matched normal mucosa, using the Illumina Human Ref-8_V2 Sentrix® BeadChip (Figure 1A and Table S1). We found that expression of *SFRP* family members was significantly reduced in nearly all human colorectal tumor samples when compared to normal controls ($p < 0.001$), a finding consistent with a previous report (Suzuki et al., 2004). In contrast, expression of *WIF-1* and *DKKs* in tumor samples did not significantly differ from controls, despite previously reported *WIF-1* and *DKK1* silencing in established colorectal cancer cell lines (Aguilera et al., 2006; He et al., 2005). Interestingly, expression of *DACT3* was reduced in all 24 tumor samples ($p < 0.001$), whereas expression levels of *DACT1* and *DACT2* did not show significant differences between tumor and control tissues ($p = 0.24$ and $p = 0.64$, respectively). Consistent with reduced expression of Wnt inhibitors leading to enhanced baseline Wnt/ β -catenin signal activation, these tumors exhibited increased expression of established β -catenin/TCF target genes, including *MYC* (He et al., 1998), *CCND1* (Tetsu and McCormick, 1999), *LEF1* (Filali et al., 2002) and *CD44* (Wielenga et al., 1999), compared to control tissues. RT-PCR analysis of 8 pairs of randomly-selected patient samples confirmed repression of *SFRP1* and *DACT3*, but not of *DACT1* in colorectal cancer compared to controls (Figure 1B). Notably, we also found reductions in *DACT2* expression in 3 out of 8 tumor samples. Thus, beyond previously-identified reductions in expression of Wnt inhibitors such as the *SFRPs*, we have found that the expression of *DACT3* is also consistently reduced in colorectal cancer. Additionally, we have found evidence that in at least some colorectal tumors, *DACT2* expression is also reduced.

SFRPs have been shown to be transcriptionally inactivated in cancer cells through promoter methylation (Suzuki et al., 2004). To determine the methylation status of the *DACT3* promoter, we performed methylation-specific PCR (MSP) analysis in the 8 colorectal tumor samples around the transcription start site as determined by 5'-RACE (Figure S1). The *DACT3* promoter contains a CpG island (Figure 1C). MSP analysis covering the entire CpG island indicates a lack of DNA methylation at the *DACT3* promoter in colorectal tumor samples (Figure 1C). As a positive control, using the same technique we confirmed that the promoter region of *SFRP1* is methylated in these same tumor samples (Figure 1C). This finding suggests that although *DACT3* expression is reduced in colorectal cancer, this occurs independently of the DNA methylation previously implicated in gene silencing in these cells.

To determine whether the above observations are recapitulated in colorectal cancer cell lines, we performed RT-PCR analysis of the *DACT* genes and of *SFRP1* in 7 such lines (Figure 1D). Unlike *SFRP1*, which is consistently silenced in colon cancer, *DACT3* shows a basal level of expression that varies in different cell lines. Notably, expression of the other two *DACT* family members, *DACT1* and *DACT2*, was also lost in several of these cell lines, though this was not true in the primary tumor tissues examined above. We accordingly examined the methylation status of all three *DACT* genes in these colorectal cancer cell lines. As in the primary tumor samples, the *DACT3* promoter is unmethylated in all the cell lines tested, whereas *DACT1* and *DACT2* promoters were found to be partially and fully-methylated, respectively (Figure 1E). Bisulfite genomic sequencing in the RKO and HT29 cancer cell lines confirmed the results of this MSP analysis, showing partially and nearly completely methylated CpGs in the *DACT1* and *DACT2* promoters respectively, but almost no methylated cytosines in the *DACT3* promoter (Figure 1F).

The DNMT inhibitor 5-aza-2'-deoxycytidine (5-AzaC) was used to pharmacologically interfere with promoter methylation in the HCT116 colorectal cancer cell line. 5-AzaC treatment decreased methylation at the *DACT1* and *DACT2* promoters (Figure 1G), leading to the increased expression of *SFRP1*, *DACT1* and *DACT2*, but not *DACT3* (Figure 1H). Similarly, a HCT116 cell line in which the DNA methyltransferase genes *DNMT1* and *DNMT3B* were genetically disrupted (Rhee et al., 2002) showed decreased promoter methylation (Figure 1G;

DKO) and increased expression (Figure 1H) of *DACT1*, *DACT2* and *SFRP1* but no obvious change in *DACT3* (Figures 1G and H). A similar result was also obtained in DLD1 cells (Figure 1H). These results support the conclusion that unlike *SFRP1* and the *DACT1* and *DACT2* genes, promoter methylation does not contribute to the epigenetic repression of *DACT3* in colorectal cancer cells. Furthermore, we found that in patient tumor samples *DACT1* promoter was not methylated and *DACT2* promoter methylation is only detected in several tumor samples with reduced *DACT2* expression (data not shown). Thus, lack of methylation of *DACT1/2* in clinical tumor samples we examined may explain why they are not downregulated in these tumors in general.

Epigenetic repression of *DACT3* is associated with bivalent histone modifications

The above data suggest that epigenetic repression of *DACT3* in colon cancer might involve an alternative mechanism, such as histone modification. To determine if chromatin status is associated with *DACT3* repression, we used a chromatin immunoprecipitation (ChIP) assay coupled with quantitative PCR to characterize potentially involved chromatin marks. To this end, we designed a panel of 8–10 primer pairs covering a >7 kb region close to the transcription start site (TSS) of each of the three *DACT* genes, and searched for the presence of histone marks, including the repressive marks H3K27me3, H3K9me3, H3K9me2, and H4K20me3 as well as the activating marks H3K4me3 and H3K9/14ac (Figure 2A). Abundant enrichment of the repressive H3K27me3, and to a lesser extent repressive H4K20me3, was detected 500 bp downstream of the TSS of *DACT3* in HT29 cells. In addition, a weaker H3K27me3 was also detected in the more upstream promoter region of *DACT3*. This finding is in agreement with several recent genome-wide studies showing that the majority of H3K27me3 is detected in the proximal downstream region of the TSS in both cancer and embryonic stem cells (Pan et al., 2007; Yu et al., 2007; Zhao et al., 2007). In contrast, no repressive H3K9 methylation marks were detected in the *DACT3* promoter region in HT29 cells.

The activating mark H3K4me3 was also detected at high levels near the *DACT3* TSS in HT29 cells, suggesting that the *DACT3* promoter is simultaneously modified by both repressive and activating (bivalent) histone methylation events in these cells. Such bivalent histone states have previously been correlated with genes transcribed at low levels (Azura et al., 2006; Bernstein et al., 2006; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). If this is also true for the *DACT3* locus, we would predict that the presence of repressive H3K27me3 should inversely correlate with *DACT3* expression levels. Consistent with this hypothesis, high level of H3K27me3 was also detected at *DACT3* in SW480 cells that express low levels of *DACT3*; to a lesser extent in RKO cells that have modest *DACT3* expression (Figure 2B). Moreover, only high level of H3K4me3 (but not H3K27me3) was detected at *DACT3* in normal human intestinal epithelial cells (FHs 74 Int) and two other none-cancerous cell lines, breast epithelial MCF10A and lung fibroblast MRC5 (Figure 2C), suggesting that this bivalent modification at *DACT3* is cancer specific. To further confirm that the *DACT3* promoter is in a bivalent histone state in cells where its expression is repressed, we have conducted whole genome mapping of major histone marks in SW480 cells using ChIP-Seq Solexa technology. This high resolution mapping of histone modifications clearly demonstrates the co-modification of H3K27me3 and H3K4me3 at *DACT3* (Figure S2).

Enrichments of H3K4me3, and to a lesser degree, H3K27me3, were also detected at *DACT1* but no enrichment peaks of these histone marks, including H3K4me3, was detected at the *DACT2* locus (Figure 2A). In general for the *DACT* gene family, our results suggest that the level of H3K4me3 is inversely correlated with the DNA methylation state: H3K4me3 is detected at the *DACT1* promoter (which is partially methylated), and at the *DACT3* promoter (which is not methylated), but not at the *DACT2* promoter (which is fully methylated) (Compare Figure 1F and Figure 2). This finding agrees with recent reports that DNMT preferentially

binds to unmethylated H3K4 (Ooi et al., 2007) and that methylation of H3K4 tends to protect surrounding nucleotides from methylation (Weber et al., 2007). Along with the earlier data showing that expression of *DACT3* is insensitive to CpG island methylation, our data is consistent with the hypothesis that in colon cancer cells, *DACT3* is repressed primarily through histone modifications, and specifically that the *DACT3* locus in such cells exists in a bivalent chromatin state simultaneously containing both repressive and activating histone modifications.

Robust de-repression of *DACT3* by a pharmacological approach inhibiting both histone methylation and deacetylation

We have recently reported that the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) depletes PRC2 components and inhibits histone methylation, including repressive H3K27me3 and H4K20me3 (Tan et al., 2007). We set out to test whether DZNep, alone or in combination with the histone deacetylase inhibitor Trichostatin A (TSA), the DNMT inhibitor 5-AzaC, or both, could restore *DACT3* expression in colorectal cancer cells. To most accurately measure changes in gene expression, we used the Illumina beadarray which allows for accurate measurement of transcript levels without intermediate nucleic acid amplification steps. We found that when used as single agents these drugs minimally induce expression of *DACT3* in DLD1 cells (Figure 3A). However, combined treatment with DZNep and TSA strongly induces *DACT3* expression, whereas other combinations such as DZNep/Aza or TSA/Aza fail to do so (Figure 3A). By contrast, DZNep/TSA combination only induced a modest increase in *DACT1* expression (Figure 3B). Expression of *DACT2*, on the other hand, was only induced by treatments containing 5-AzaC (Figure 1H and Figure 3B), consistent with its epigenetic silencing by more typical promoter methylation.

To determine the specificity of DZNep/TSA combination treatment for *DACT3* de-repression versus changes in expression of other known Wnt/ β -catenin pathway inhibitors, we again analyzed Illumina gene expression data using RNA from 2 colon cancer cell lines (DLD1 and HT-29); untreated or treated with DZNep, TSA or both. This analysis revealed that *DACT3* is the only Wnt/ β -catenin pathway inhibitor strongly induced by DZNep/TSA treatment and that this occurred in both colon cancer cell lines (Figure 3B and Table S2). Together, our findings show that *DACT3* is distinguished from other Wnt pathway inhibitors in that its repression in colon cancer cells seems to be associated with the bivalent histone modifications but not DNA methylation, and accordingly it can be robustly de-repressed by a pharmacologic approach that exclusively targets histone modifications.

In order to better understand the mechanism whereby the DZNep/TSA drug combination reactivates *DACT3* expression, we examined histone modification profiles in treated and untreated cells by Western blot (Figure 3C). As previously reported, DZNep treatment alone results in strong reduction of H3K27me3 and H4K20me3, while having little effect on H3K9me3 (Tan et al., 2007). Although the combination treatment resulted in some mild inhibition of H3K9me3, the most notable synergistic change compared to treatment with DZNep or TSA alone, was robust induction of H3K9/14 acetylation (Figure 3C). Interestingly, H3K4me3 is also induced by this combination treatment, irrespective of a slight decrease with DZNep treatment alone. Thus, the pharmacologic combination of DZNep with TSA causes an intriguing global shift in histone modifications: it reduces certain repressive histone marks (H3K27me3, H4K20me3 and H3K9me3) while dramatically increasing some activating histone marks (H3K9/14ac and H3K4me3). Mechanistically, this suggests the existence of crosstalk between these chromatin marks, such that inhibition of repressive histone methylation by DZNep creates a favorable chromatin environment for histone acetylation induced by TSA. The magnitude of the effects observed on general histone profiles in these treated cells further

suggests that this phenomenon is widespread throughout the genome. This in turn leads to increased expression of specific target genes, prominently including *DACT3*.

We used ChIP to further assess changes in histone modifications specifically at the *DACT3* locus in response to DZNep/TSA combination treatment. Consistent with the global changes in modified histone levels found by Western blot analysis, cells treated with DZNep/TSA had a decrease in H3K27me3 and H4K20me3, and a concomitant increase in H3Kme3 and H3K9/K14ac at the *DACT3* locus (Figure 3D). Such effects were much weaker at the *DACT1* locus, and thus correlate well with the relative effects of this pharmacologic treatment on *DACT3* and *DACT1* gene expression respectively. The striking changes in histone methylation and acetylation marks at the *DACT3* locus are consistent with and help to explain the equally striking changes in *DACT3* expression levels following DZNep/TSA treatment.

To summarize, our biochemical, pharmacologic, and expression data all support a model in which repression of *DACT3* expression occurs via a bivalent histone domain. Furthermore, this repression can be effectively reversed by a combined pharmacological approach that simultaneously inhibits both histone methylation and deacetylation, resulting in a major change in chromatic structure at a subset of such bivalently modified genes, prominently including the *DACT3* locus.

De-repression of *DACT3* is associated with inhibition of Wnt/ β -catenin signaling and massive apoptosis in colorectal cancer cells

Based on a previously published study (Zhang et al., 2006), one effect of increased DACT protein levels might be degradation of the Dishevelled (DVL) protein, which is central to Wnt signal transduction (Bilic et al., 2007; Logan and Nusse, 2004). Activation of the Wnt/ β -catenin pathway in cancer cells and in other contexts is molecularly observable as accumulation of unphosphorylated non-membrane associated β -catenin in the nucleus and cytoplasm (Peifer and Polakis, 2000; Polakis, 2007). Accordingly, we examined the effects of our drug treatment on DVL2 and β -catenin levels. DVL2 was arbitrarily chosen as a representative of the DVL gene family as it is one of three functionally-redundant, conserved DVL family members expressed in all or most cell types (Hamblet et al., 2002). Consistent with observed changes in transcript levels, *DACT3* protein levels were markedly increased (in both SW480 and DID1 cells) upon DZNep and TSA combination treatment as determined by Western blot analysis (Figure 4A and Figure S3). As predicted, the combination treatment resulted in a decrease in DVL2 levels. In contrast, treatment with either DZNep or TSA alone did not cause such changes (Figure 4A). Concomitantly, levels of activated (non-phosphorylated) β -catenin dropped in DZNep/TSA-treated cells by Western blot (Figure 4A). This was confirmed by immunocytochemistry showing diminished nuclear β -catenin staining upon treatment with DZNep/TSA (Figure 4B). Finally, the expression of TCF/ β -catenin target genes, including *MYC*, *LEF*, *CCND1* and *CD44*, was markedly decreased in DZNep/TSA treated cells, but not in cells treated with either DZNep or TSA alone (Figure 4C and Table S3). These findings uniformly indicate that Wnt/ β -catenin signaling is inhibited by DZNep/TSA combination treatment. Furthermore, we found that the decrease of β -catenin upon DZNep/TSA can be effectively rescued by treatment of cells with small molecule inhibitor of GSK-3, while the downregulation of DVL2 remained unaffected (Figure S4). This suggests that *DACT3*-DVL2 routes through GSK-3 to regulate β -catenin stability. Among 81 genes whose expression was increased by DZNep/TSA treatment in all the three cancer cell lines, *DACT3* is by far the most heavily induced (Table S4). To our knowledge no other gene in this list is directly relevant to Wnt/ β -catenin signaling. Taken together, our results support that DZNep/TSA combination treatment decreases Wnt/ β -catenin signal transduction in colorectal cancer cell lines by increasing *DACT3* gene expression and protein levels, secondarily destabilizing endogenous

DVL proteins necessary for efficient Wnt signal transduction. Conversely, they suggest that repression of *DACT3* is a key epigenetic event in colorectal cancer formation.

Inhibition of Wnt/ β -catenin signaling is expected to block the pro-survival pathway and induce apoptosis in cancer cells that are addicted to this pathway (Fujii et al., 2007; He et al., 2005). Indeed, we found that inhibition of Wnt/ β -catenin signal transduction by DZNep/TSA was accompanied by a strong synergistic induction of cell death in DLD1 and HT29 cells, as assessed by propidium iodide (PI) and fluorescence-activated cell sorting (FACS) (Figure 4D). Similar results were obtained using other colon cancer cell lines (data not shown). In contrast, cells treated with DZNep/Aza, a treatment that does not efficiently de-repress *DACT3* expression, did not undergo comparable levels of cell death. Similarly, addition of 5-AzaC to the DZNep/TSA combination, which does not produce further increases in *DACT3* gene expression, also does not produce additional increases in cell death. This suggests that modulation of DNA methylation by 5-AzaC and resultant effects on other potential gene targets does not contribute to further effects on Wnt/ β -catenin signaling, and that induction of *DACT3* alone by DZNep/TSA is associated with maximal cell death. The cell death induced by DZNep/TSA was further determined to be apoptotic. As shown in Figure 4E, DZNep/TSA combination treatment, but not single agent treatment, resulted in a dramatic activation of Caspase 3 in HT29 cells (Figure 4E). Moreover, the combination treatment induced a sharp drop in mitochondrial transmembrane potential (MTP) ($\Delta\Psi_m$), indicative of mitochondrial dysfunction that is characteristic of apoptosis (Figure 4F).

The specific effects of DZNep/TSA treatment on histone modifications, *DACT3* gene expression, activated β -catenin protein levels, and apoptosis were also seen in treatments combining DZNep with other HDAC inhibitors such as PXD101 and suberoylanilide hydroxamic acid (SAHA). This shows that the effects of this pharmacological strategy that we have defined depend on the combined action of DZNep with an HDAC inhibitor, and are not idiosyncratic consequences of TSA administered in combination with DZNep (Figure S5).

Functional validation of *DACT3* as a critical regulator of Wnt/ β -catenin signaling

To assess whether *DACT3* transcriptional de-repression is required to decrease Wnt/ β -catenin signaling in treated colorectal cancer cells, we generated cell lines derived from DLD1 that stably express a short-hairpin RNA targeting *DACT3*. Levels of the *DACT3* mRNA following DZNep/TSA treatment were greatly diminished in two DLD1 clones expressing the *DACT3* shRNA compared to control shRNA cells (Figure 5A). Western blot analysis indicated that DZNep/TSA-induced effects on both DVL2 and unphosphorylated β -catenin levels were diminished in *DACT3* shRNA cells (Figure 5A). Moreover, when apoptosis was assayed, the induction of apoptosis by DZNep/TSA was markedly reduced in cell lines expressing *DACT3* shRNA (Figure 5B). These *DACT3* knockdown effects are unlikely to be caused by off-target effects of the siRNA, because they were also observed in SW480 cells transiently transfected with two other independent *DACT3* siRNAs (Figure 5C). By contrast, knockdown of *DACT1*, which shows only a slight increase upon DZNep/TSA treatment, had no inhibitory effect on apoptosis (Figure 5D). In summary, our results indicate that transcriptional de-repression of *DACT3* contributes to inhibition of Wnt/ β -catenin signal transduction and to apoptosis following DZNep/TSA treatment of colorectal cancer cells.

We next set out to directly test the function of *DACT3* in regulating Wnt/ β -catenin signal transduction. *DACT* family members in various species have previously been shown to interact with DVL proteins through a highly-conserved C-terminal motif and to negatively regulate β -catenin function (Cheyette et al., 2002; Zhang et al., 2006). To confirm that *DACT3* also interacts with DVL proteins, we performed co-immunoprecipitation experiments by transfecting SW480 cells with expression vectors for Flag-tagged *DACT3* and HA-tagged Dvl2. Under these conditions using either tag antibody, Dvl2 efficiently immunoprecipitates

with DACT3, and conversely DACT3 efficiently immunoprecipitates with Dvl2 (Figure 6A). Furthermore, co-transfection of Dvl2-HA with DACT3-Flag led to a marked decrease in Dvl2-HA protein expression compared to Dvl2-HA expressing cells co-transfected with an empty vector (Figure 6B). These results demonstrate that, as predicted from homology with other DACT family members, DACT3 can indeed interact with DVL family members as exemplified by Dvl2. They further show that this interaction can reduce DVL protein stability, at least under these co-transfection conditions.

We similarly investigated the effect of ectopic *DACT3* expression on β -catenin levels in SW480 cells using confocal immunocytochemistry. SW480 cells expressing Myc-tagged DACT3 or DACT1 had nearly undetectable levels of nuclear β -catenin, whereas untransfected cells or cells transfected with a non-relevant gene product, Myc-tagged RPS27L, retained high levels of nuclear β -catenin (Figure 6C). Moreover, SW480 cells ectopically expressing DACT3 displayed condensed nuclei typical of apoptosis. These results demonstrate that ectopically expressed *DACT3*, like other Dact family members (Cheyette et al., 2002; Hikasa and Sokol, 2004; Zhang et al., 2006), can negatively regulate Wnt/ β -catenin signaling, including in colorectal cancer cells.

To determine if DACT3 suppresses cell growth as a result of inhibition of oncogenic Wnt/ β -catenin signaling, we performed the colony formation assay with DLD1 cells transfected with a *DACT3* expressing plasmid or the control empty vector. Cells transfected with *DACT3* show a dramatic decrease in colony numbers compared to control cells (Figure 6D). This result further demonstrates that DACT3 functions as a potential tumor suppressor in colon cancer.

Discussion

The present study uncovers an epigenetic event that contributes to the constitutive activation of Wnt/ β -catenin signaling in human colorectal cancer. We show that transcriptional repression of the *DACT3* gene occurs frequently both in colorectal cancer cell lines and in patient-derived tumors. Our analysis indicates that *DACT3*, together with *SFRPs*, might be a key epigenetic regulator of the Wnt/ β -catenin signaling pathway in this disease process. This study thereby establishes *DACT3* as a potentially important target for cancer therapies aimed at controlling aberrant Wnt/ β -catenin signaling.

Unlike the *SFRP* genes whose expression is often completely silenced by promoter DNA methylation, *DACT3* appears to be expressed at low levels in colon cancer cell lines. We provide evidence to show that this epigenetic event occurs through a bivalent histone modification that contain both repressive (H3K27me3) and activating (H3K4me3) histone marks at the *DACT3* locus and does not involve or require methylation of the promoter DNA. As a result of this epigenetic regulation, levels of *DACT3* can be strongly induced by a pharmacological treatment that targets histone modifications: specifically, combination treatment that simultaneously interferes with both histone methylation and deacetylation. By contrast, this treatment does not reactivate genes silenced predominately by DNA methylation, such as *SFRP1* or *DACT2*, and only modestly induce *DACT1* whose repression in colon cancer cells is linked to both DNA methylation and histone modifications. This data suggest that this combination treatment of DZNep/TSA preferentially reactivate genes predominately repressed by bivalent histone modifications with minimum DNA methylation.

The bivalent chromatin has been previously described in both embryonic stem (ES) cells and some differentiated cells, where they are in general associated with genes expressed at low levels (Azuara et al., 2006; Barski et al., 2007; Bernstein et al., 2006; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). Some tumor suppressor genes with bivalent histone marks in ES cells lose the H3K4me3 mark during oncogenesis, but instead become fully silenced

through DNA methylation (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). Our data suggest that a bivalent chromatin state occurred in cancer cells might also contribute to cancerous transformation. Importantly, this epigenetic modification at *DACT3* locus appeared to be cancer specific as we did not observe the same modifications at *DACT3* locus in normal intestinal epithelial cells. Genes found in such a bivalent chromatin state in cancer cells (such as *DACT3*) therefore represent unique therapeutic targets. Unlike tumor suppressors that are silenced by DNA methylation, genes carrying a bivalent chromatin such as *DACT3* may be more subject to manipulation by treatments such as DZNep/TSA that target both histone methylation and deacetylation. Identifying these alternately-regulated tumor suppressor genes is also important because they are likely to be insensitive to therapies that only target DNA methylation, such as Aza.

Although highly speculative, it is possible that the chromatin pattern we have observed at the *DACT3* locus in our colorectal cancer cells is part of the molecular signature of stem cell-like cancer cells. There is evidence that Wnt/ β -catenin signaling plays a central role in the maintenance of epithelial stem cells and of early progenitors (de Lau et al., 2007; Fodde and Brabletz, 2007). There is also data suggesting that the initial epigenetic event(s) that upregulate Wnt/ β -catenin signaling may occur in colorectal adenomas before they acquire fully-transforming APC mutations (Siu et al., 1999; Suzuki et al., 2004). Bivalent histone modification at *DACT3* could be one such epigenetic event. The combined pharmacologic approach we have described, which targets an epigenetic signature characteristic of colorectal cancer cells and abrogates Wnt/ β -catenin signaling, may have the potential to target cancer stem cells that rely on this mechanism of gene silencing and that require high levels of Wnt/ β -catenin signaling activity for their self-renewal and survival.

Our study illustrates the diversity and complexity of epigenetic mechanisms involved in gene repression in cancer cells. Use of DZNep as a histone methylation inhibitor in combination with other chromatin remodeling compounds may make it possible to discover other cancer genes regulated through various epigenetic mechanisms. The combined effects of DZNep and the HDAC inhibitor TSA on overall histone modification profiles is provocative, because together this drug combination appears to switch a repressive chromatin state into an active one by simultaneously reducing repressive histone marks (H3K27me3) and increasing activating marks (H3K4me3 and H3K9/14ac). This pharmacologic intervention, together with a DNA methylation inhibitor, might therefore have the potential to revert a globally “malignant” chromatin state found in some cancer cells into a more normal “benign” one. Although it remains to be biochemically determined how DZNep/TSA treatment generates such strong synergy in histone acetylation, we propose that this reflects direct cross-talk between these two types of histone modification. We further predict that such pharmacologic epigenetic “reprogramming” of histone modification profiles across the genome can lead to profound changes in gene expression, affecting multiple signaling pathways simultaneously. Indeed, our microarray data shows that *DACT3* is not the only gene regulated in this manner; the expression of at least 81 other genes was significantly affected by combined DZNep/TSA treatment. It is possible that inhibition of Wnt/ β -catenin signaling cooperates with other signaling effects to yield the maximal apoptotic response observed upon this combination treatment.

We show that increasing the levels of *DACT3* protein in colorectal cancer cells, either through pharmacologic de-repression or via ectopic expression, results in robust degradation of DVL2 and to decreases in activated β -catenin. This *DACT3*-DVL2 signaling interaction might route through GSK-3 to regulate β -catenin stability; in support of this we have found that a small molecule inhibitor of GSK-3 can rescue the decreases in activated β -catenin caused by DZNep/TSA treatment. As reported here we have also found that decreases in activated β -catenin caused by increasing *DACT3* can occur even in the presence of APC mutations. This finding

is consistent with numerous reports suggesting that deregulated β -catenin phosphorylation and degradation still takes place in colorectal cancer cells carrying APC mutations (Calviello et al., 2007; Rice et al., 2003; Suzuki et al., 2004; Yang et al., 2006). In particular, it has been shown that restored expression of SFRP1/2 can effectively degrade β -catenin in colorectal cancer cells carrying these downstream mutations (Calviello et al., 2007; Rice et al., 2003; Suzuki et al., 2004). These findings, together with ongoing studies suggest that there are alternate molecular mechanisms that contribute to β -catenin regulation independently of APC in colorectal cancer cells.

Our data also suggest that multiple abnormal epigenetic events might contribute to aberrant activation of the Wnt/ β -catenin signaling pathway in colon cancer. These multiple events might occur in the same cell, or they may be present in different cells within a tumor. By increasing heterogeneity in a tumor cell population, epigenetic events may contribute to cancer progression, and also contribute to treatment resistance and cancer recurrence.

In short, this study demonstrates that epigenetic repression of *DACT3* leads to aberrant Wnt/ β -catenin signaling in colorectal cancer cells. Our data represent an important advance toward understanding how a previously unknown epigenetic event contributes to deregulation of Wnt/ β -catenin signaling in colorectal cancer. This work also provides an important proof-of-principle that such epigenetic events can be specifically targeted by pharmacologic strategies to yield robust effects on Wnt/ β -catenin signaling with important consequences for cancer eradication.

Experimental procedures

Samples, cell lines and drug treatment

Human tissue samples were obtained from Singapore Tissue Network using protocols approved by institutional Review Board of National University of Singapore; informed consent was obtained from each individual who provided the tissues. The colorectal cancer cell lines and non-transformed cell lines used in this study were purchased from the American Type Culture Collection (Manassas, VA). HCT116 cells with genetic disruption of DNMT1 and DNMT3B (HCT116 DKO) were kindly provided by Dr. Bert Vogelstein (Johns Hopkins University, MD). For drug treatment, cells were seeded the day before the drug treatment. Cells were treated with 5 μ M 3-Deazaneplanocin A (DZNep) (obtained from Dr. Victor E. Marquez at National Cancer Institute, USA) or 5 μ M 5-aza-2'-deoxycytidine (5-AzaC; Sigma) for 72 hours and Trichostatin A (TSA; Cell Signaling) at 100–200 nM for 24 hours. For 5-AzaC treatment, the medium was replaced with freshly added 5-AzaC for every 24 h. For co-treatment of cells with DZNep and TSA, DZNep was added for 24 hours followed by TSA for additional 24 hours for gene expression analysis and 48 hours for FACS analysis.

Mapping of *DACT3* transcription start sites and cloning of full-length *DACT3* cDNA

10 μ g of total RNA was isolated from HEK293 cells with RNeasy Mini Kit (Qiagen). *DACT3* transcription start sites were mapped by RNA ligation mediated 5'RACE using FirstChoice RLM-RACE kit (Ambion) according to the manufacturer's protocol with the exception of reverse transcription and PCR steps. Reverse transcription after linker ligation was carried out at 64°C for 1h using Thermo-X polymerase (Invitrogen) and a gene specific oligo: 5-GACCCAGGCGACCATAGGAGCTGGATC-3'. Nested PCR was carried out using PfuUltraPhusion polymerase (Stratagene) with forward primers provided by the FirstChoice RLM-RACE kit and gene specific reverse primers: 5'-GCTGGATCCAGAGAAGCCACTGTCCCA-3' and 5'-CACAGAAGGTTGAGGGTGGTGAATCTGGACCT-3'. PCR products were cloned into pCR-BluntII-TOPO vector (Invitrogen) and sequenced with M13 primers. A tagged *DACT3*

expression construct containing the longest open reading frame, based on mRNA start site mapping was generated for overexpression studies. Full-length *DACT3* coding region was amplified by RT-PCR using 5 µg of total mRNA from HEK293 cells and following primers: 5'-ATTGAATTCAATGATCCGGCCTTCTCGTTCCCGGT-3' and 5'-ATTAGATCTTCACTGTAGTCATGACCTTGAGAGAACCCGA-3'. The PCR product was cloned into p3xFLAG-CMV10 between EcoRI and BglII sites and sequenced.

RNA interference

The SMARTpool® siRNA targeting *DACT3* and the non-targeting control were purchased from Dharmacon (Lafayette, CO). A separate *DACT3* siRNA targeting the following sequence: 5'-GGUUCUCUCAAGGUCAUGA-3' was obtained from Sigma-Prologo. To generate *DACT3* shRNA stable cells, a *DACT3* siRNA sequence (GGAGAAUCGCCUGCCUUCA) was cloned into the pSIREN-RetroQ retroviral expression vector. The pSIREN-RetroQ-Neg Vector was used as negative control shRNA (BD Bioscience) and cells were selected and expanded as described (Tan et al., 2007).

Immunoblot analysis

Immunoblotting was performed as described previously (Tan et al., 2007). The blots were probed with the following antibodies: anti-H3K27me3 (07-449), anti-H3K9me3 (07-442), anti-H3K9/K14 ac (06-599), anti-H3K4me3 (07-473) and anti-active β-catenin(05-665), were purchased from Upstate. Anti-H4K20me3 (ab9053) was from Abcam. Anti-β-catenin (6B3) and anti-H3 (3H1) were from Cell Signaling and anti-DVL2 (sc-8026) was from Santa Cruz. The rabbit polyclonal antibody to *DACT3* was raised against a 14 amino acid peptide from human *DACT3* (LSLESGGLEQESGR) and was purified through affinity column.

Transfection and immunoprecipitation

SW480 cells were transiently transfected using Fugen 6.0 (Roche). At 48h post-transfection, the cells were lysed with 1ml of lysis buffer (20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 25 mM NaF, 1% Triton X-100) plus protease inhibitors (Roche) for 30 min at 4°C. After 12,000 g centrifugation for 30 min, the lysates were immunoprecipitated with anti-FLAG M2 agarose affinity gel (Sigma) or anti-HA affinity matrix (Roche) for overnight at 4°C. The precipitants were washed three times with washing buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) and the immune complexes eluted with sample buffer containing 1% SDS for 5 min at 95°C and analyzed by SDS-PAGE. Immunoblotting was performed with primary antibodies against HA tag (sc-805, Santa Cruz) or FLAG tag (F1804, Sigma).

Apoptosis and Flow Cytometric analysis

Cells were harvested and fixed in 70% ethanol. Fixed cells were stained with propidium iodide (50 µg/mL) after treatment with RNase (100 µg/mL). The stained cells were analyzed for DNA content by fluorescence-activated cell sorting (FACS) in a FACSCalibur (Becton Dickinson Instrument, San Jose, CA). Apoptotic sub-G1 fraction was quantified using the CellQuest software (Becton Dickinson). To measure the mitochondrial transmembrane potential (MTP), cells were stained with JC-1, according to the manufacturer's instructions (BD Bioscience), and cells positive for JC-1 detection were measured using CellQuest software (BD Bioscience). To measure caspase-3 activity, cells were fixed with Cytotfix/Cytoperm solution (BD Biosciences) as instructed and then stained with fluorescein isothiocyanate-conjugated rabbit anti-active caspase-3 monoclonal antibody (BD Biosciences). Quantification of cells positive for the caspase-3 detection was performed by flow cytometry.

Microarray gene expression analysis and semi-quantitative RT-PCR

Total RNA was isolated using Trizol (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen). Reverse transcription was performed using an RNA Amplification kit (Ambion). The microarray hybridization was performed using the Illumina Gene Expression Sentrix®BeadChip HumanRef-8_V2 and data analysis was performed using GeneSpring software from Agilent Technologies as described (Tan et al., 2007). For RT-PCR, total RNA was reverse-transcribed using oligo(dT)12–18 primer with Superscript II reverse transcriptase (Invitrogen). 100 ng of cDNA was used for PCR and the Primer sequences are shown in Table S5. The microarray data have been submitted to the GEO public database (accession number GSE10972).

DNA methylation analysis

The CpG island DNA methylation status was determined by PCR analysis after bisulfited modification and followed by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS)(Yoshikawa et al., 2001). All bisulfite genomic sequencing and methylation-specific PCR primers were designed to be close transcription start sites and in the CpG islands of the genes investigated. Primer sequences are shown in Table S5.

Chromatin immunoprecipitation (ChIP) assays

ChIP assays were performed as described previously (Zhao et al., 2005). The immunoprecipitated DNA was quantitated by real-time quantitative PCR using the PRISM 7900 Sequence Detection System (Applied Biosystems). Primer sets were chosen to amplify approximately 100–150 bp around the indicated region. We used the following antibodies in the ChIP study: anti-H3K27me3 (Upstate), anti-H3K9me3 and anti-H3K9me2 (Abcam), anti-H3K20me3 (Upstate), anti-H3K9/K14ac and anti-H3K4me3 (Upstate). The enrichments of these histone marks at the examined regions were quantitated relative to the input amount. To compare the two pools of DNA materials, from cells untreated and from cells treated, a further normalization of the Δ Ct values against a region that shows low background enrichment was performed. The sequences of the PCR primers are shown in Table S5.

Immunofluorescence Staining and Confocal Microscopy

The cells were seeded in 4-well or 8-well culture chamber slides. After treatment or transfection for 72h, cells were fixed with 3.7% paraformaldehyde in PBS and permeabilized with 0.2% Triton-X100. Cells were sequentially incubated with primary antibodies (anti-Myc or anti- β -catenin) and Alexa Fluor 488 or Alexa Fluor 546-conjugated secondary antibodies (Invitrogen) for 1 hour each and mounted in Fluorsave (Merck) mounting medium. DRAQ5 (Biostats, UK) was diluted in mounting medium for nuclear staining. The stained cells were examined by Zeiss LSM510 confocal microscopy.

Colony formation assay

Colony formation assays were performed as described previously to evaluate tumor cell growth *in vitro* (Yoshikawa et al., 2001). DLD1 cells were plated at 30×10^4 per well using 6-well plates, and transfected with either pcDNA4.0-DACT3 or backbone pcDNA4.0 (2.0 μ g) using Fugen 6 (Roche) according to the manufacturer's protocol. The cells were replated in triplicates and cultured for 10–15 days in complete DMEM medium containing Zeocin (100 μ g/ml). The surviving colonies were stained with Gentian Violet after methanol fixation and visible colonies ($\times 50$ cells) were counted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Dr. Bert Vogelstein for the HCT116 DKO cells. We thank Dr Yue-Guang Chen from Qinghua University (Beijing) for providing the DACT1-myc construct and Drs. Yijun Ruan and Chiain Wei for ChIP-Seq in SW480 cells. This work was supported by the Agency for Science, Technology and Research of Singapore. Dr. Kivimäe and Dr. Cheyette were supported by grants to Dr. Cheyette from the NIH (MH01750 K08; 1R01HD055300), the Hellman Family Early Cancer Faculty Award, and the UCSF Center for Neurobiology and Psychiatry. We thank the Singapore Tissue Network for providing the human samples and Dr. Victor E. Marquez from National Cancer Institute (USA) for providing the 3-Deazaneplanocin A.

References

- Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, Garcia JM, Munoz A, Esteller M, Gonzalez-Sancho JM. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. *Oncogene* 2006;25:4116–4121. [PubMed: 16491118]
- Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merkenschlager M, Fisher AG. Chromatin signatures of pluripotent cell lines. *Nat Cell Biol* 2006;8:532–538. [PubMed: 16570078]
- Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. *Nat Rev Drug Discov* 2006;5:997–1014. [PubMed: 17139285]
- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. *Cell* 2007;129:823–837. [PubMed: 17512414]
- Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? *Nat Rev Cancer* 2006;6:107–116. [PubMed: 16491070]
- Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* 2006;125:315–326. [PubMed: 16630819]
- Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs C. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. *Science* 2007;316:1619–1622. [PubMed: 17569865]
- Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, Monego G, Ranelletti FO, Palozza P. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. *Carcinogenesis* 2007;28:1202–1209. [PubMed: 17183061]
- Cheyette BN, Waxman JS, Miller JR, Takemaru K, Sheldahl LC, Khlebtsova N, Fox EP, Earnest T, Moon RT. Dapper, a Dishevelled-associated antagonist of beta-catenin and JNK signaling, is required for notochord formation. *Dev Cell* 2002;2:449–461. [PubMed: 11970895]
- de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and colorectal cancer. *Front Biosci* 2007;12:471–491. [PubMed: 17127311]
- Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. *J Biol Chem* 2002;277:33398–33410. [PubMed: 12052822]
- Fisher DA, Kivimäe S, Hoshino J, Suriben R, Martin PM, Baxter N, Cheyette BN. Three Dact gene family members are expressed during embryonic development and in the adult brains of mice. *Dev Dyn* 2006;235:2620–2630. [PubMed: 16881060]
- Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. *Curr Opin Cell Biol* 2007;19:150–158. [PubMed: 17306971]
- Fujii N, You L, Xu Z, Uematsu K, Shan J, He B, Mikami I, Edmondson LR, Neale G, Zheng J, et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. *Cancer Res* 2007;67:573–579. [PubMed: 17234765]
- Gloy J, Hikasa H, Sokol SY. Frigo interacts with Dishevelled to transduce Wnt signals. *Nat Cell Biol* 2002;4:351–357. [PubMed: 11941372]
- Hamblet NS, Lijam N, Ruiz-Lozano P, Wang J, Yang Y, Luo Z, Mei L, Chien KR, Sussman DJ, Wynshaw-Boris A. Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure. *Development* 2002;129:5827–5838. [PubMed: 12421720]

- He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. *Oncogene* 2005;24:3054–3058. [PubMed: 15735684]
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. *Science* 1998;281:1509–1512. [PubMed: 9727977]
- Hikasa H, Sokol SY. The involvement of Frodo in TCF-dependent signaling and neural tissue development. *Development* 2004;131:4725–4734. [PubMed: 15329348]
- Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996;87:159–170. [PubMed: 8861899]
- Kwong KY, Zou Y, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. *Oncogene* 2002;21:8340–8346. [PubMed: 12447697]
- Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleff I, Pirinen S, Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. *Am J Hum Genet* 2004;74:1043–1050. [PubMed: 15042511]
- Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. *Cancer Cell* 2004;5:91–102. [PubMed: 14749129]
- Li H, Pamukcu R, Thompson WJ. beta-Catenin signaling: therapeutic strategies in oncology. *Cancer Biol Ther* 2002;1:621–625. [PubMed: 12642683]
- Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. *Nat Genet* 2000;26:146–147. [PubMed: 11017067]
- Logan CY, Nusse R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol* 2004;20:781–810. [PubMed: 15473860]
- Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature* 2007;448:553–560. [PubMed: 17603471]
- Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science* 1997;275:1787–1790. [PubMed: 9065402]
- Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nat Genet* 2007;39:237–242. [PubMed: 17211412]
- Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* 2007;448:714–717. [PubMed: 17687327]
- Pan G, Tian S, Nie J, Yang C, Ruotti V, Wei H, Jonsdottir G, Stewart R, Thomson J. Whole-Genome Analysis of Histone H3 Lysine 4 and Lysine 27 Methylation in Human Embryonic Stem Cells. *Cell Stem Cell* 2007;1:299. [PubMed: 18371364]
- Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. *Science* 2000;287:1606–1609. [PubMed: 10733430]
- Polakis P. The many ways of Wnt in cancer. *Curr Opin Genet Dev* 2007;17:45–51. [PubMed: 17208432]
- Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. *Nature* 2002;416:552–556. [PubMed: 11932749]
- Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. *Mol Cancer Ther* 2003;2:885–892. [PubMed: 14555707]
- Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. *Nat Genet* 2007;39:232–236. [PubMed: 17200670]
- Siu IM, Robinson DR, Schwartz S, Kung HJ, Pretlow TG, Petersen RB, Pretlow TP. The identification of monoclonality in human aberrant crypt foci. *Cancer Res* 1999;59:63–66. [PubMed: 9892186]

- Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. *Science* 1992;256:668–670. [PubMed: 1350108]
- Su Y, Zhang L, Gao X, Meng F, Wen J, Zhou H, Meng A, Chen YG. The evolutionally conserved activity of Dapper2 in antagonizing TGF-beta signaling. *Faseb J* 2007;21:682–690. [PubMed: 17197390]
- Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijnenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. *Nat Genet* 2002;31:141–149. [PubMed: 11992124]
- Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* 2004;36:417–422. [PubMed: 15034581]
- Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. *Genes Dev* 2007;21:1050–1063. [PubMed: 17437993]
- Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 1999;398:422–426. [PubMed: 10201372]
- van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Battle E, Coudreuse D, Haramis AP, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* 2002;111:241–250. [PubMed: 12408868]
- Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. *Nat Genet* 2007;39:457–466. [PubMed: 17334365]
- Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. *Nat Genet* 2007;39:157–158. [PubMed: 17200673]
- Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. *Am J Pathol* 1999;154:515–523. [PubMed: 10027409]
- Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. *J Biol Chem* 2006;281:17751–17757. [PubMed: 16798748]
- Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. *Nat Genet* 2001;28:29–35. [PubMed: 11326271]
- Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. *Cancer Res* 2007;67:10657–10663. [PubMed: 18006806]
- Zhang L, Gao X, Wen J, Ning Y, Chen YG. Dapper 1 antagonizes Wnt signaling by promoting dishevelled degradation. *J Biol Chem* 2006;281:8607–8612. [PubMed: 16446366]
- Zhang L, Zhou H, Su Y, Sun Z, Zhang H, Zhang Y, Ning Y, Chen YG, Meng A. Zebrafish Dpr2 inhibits mesoderm induction by promoting degradation of nodal receptors. *Science* 2004;306:114–117. [PubMed: 15459392]
- Zhao X, Han X, Chew J, Liu J, Chiu K, Choo A, Orlow Y, Sung W, Shahab A, Kuznetsov V, et al. Whole-Genome Mapping of Histone H3 Lys4 and 27 Trimethylations Reveals Distinct Genomic Compartments in Human Embryonic Stem Cells. *Cell Stem Cell* 2007;3:286. [PubMed: 18371363]
- Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. *Proc Natl Acad Sci U S A* 2005;102:16090–16095. [PubMed: 16243973]




Figure 1. Loss of DACT3 expression in colon cancer independently of DNA methylation
A: Hierarchical clustering of Wnt inhibitors (upper) and Wnt/ β -catenin target genes (lower) in human colorectal tumors (T) and matched normal mucosa (N).
B: RT-PCR analysis of *SFRP1* and *DACT1*, 2 and 3 from random-selected 8 pairs of human colorectal tumor and matched mucosa.
C: Methylation status of *SFRP1* and *DACT3* in 8 tumor determined by methylation specific PCR (MSP) assay. M1, M2, M3 and M4 represent the examined PCR regions covering the entire CpG island of *DACT3* promoter.
D: RT-PCR analysis of *SFRP1* and *DACT1*, 2 and 3 in a panel of colorectal cancer cell lines compared to the normal tissue.
E: Methylation status of *SFRP1* and *DACT1*, 2 and 3 in colorectal cancer cell lines.
F: Determination of methylation status of CpG sites by sequencing of bisulfite-modified DNA from normal and colorectal cancer cell lines. Arrows indicate the transcription start sites. Open cycles represent unmethylated CpGs; closed cycles denote methylated CpGs.
G: MSP analysis of *DACT1*, 2 and 3 promoters in HCT116 cells untreated or treated with 5-AzaC and in HCT116-*DNMT1/DNMT3b*^{-/-} (DKO) cells.

H: RT-PCR analysis of *SFRP1* and *DACT1, 2 and 3* in HCT116 and DLD1 cells treated with 5-AzaC (5 uM) for 3 days and in DKO cells.




Figure 2. Histone modifications at *DACT1*, *2* and *3* in colon cancer cells

ChIP assays were performed using antibodies against the indicated histone modifications and analyzed by quantitative PCR. Genomic DNA fragments covering the -3.5 kb to $+3.5$ kb region with respect to the transcription start site of *DACT1*, *2* and *3* for PCR analysis were indicated with numbers. The relative enrichments (bound/input) (Mean \pm SD. of triplicate measurement) encompassing the indicated regions is shown for each histone marks at each gene locus.

A: Histone marks at the *DACT1-3* loci in HT-29 cells.

B: Enrichments of H3K27me3 and H3K4me3 at the *DACT3* locus in SW480 and RKO cells.

C: Enrichments of H3K27me3 and H3K4me3 at the *DACT3* locus in normal human intestinal epithelial cells (FHs 74 Int), non-cancerous breast epithelial MCF10A cells and lung fibroblast MRC5 cells.




Figure 3. Effects of combination of DZNep and TSA on *DACT3* and histone modifications

A: *DACT3* mRNA expression analysis using Illumina Beadarray in DLD1 cells treated with 5 μ M DZNep, 5 μ M 5-AzaC, 200 nM TSA or their combinations. The data shown represents Mean \pm SD of three independent experiments.

B: Indicated colorectal cancer cell lines were treated with DZNep, TSA or both. RNA was harvested and subjected to array analysis. Changes of expression of known Wnt/ β -catenin antagonists are shown.

C: Immunoblotting analysis of bulk histone modifications induced by DZNep, TSA or both in HT29 cells and SW480 cells.

D: ChIP analysis of indicated the changes of histone marks at the *DACT1* and *DACT3* loci in HT29 cells untreated or treated with DZNep/TSA. The values represent the normalized enrichments against the changes of a low background region before and after the drug treatment. The data represent Mean \pm SD of three independent experiments.




Figure 4. Combination of DZNep and TSA results in blockade of Wnt/β-catenin signaling and massive apoptosis in colorectal cancer cells

A: Immunoblot analysis of DACT3, DVL2, total β-catenin, and non-phosphorylated β-catenin (Active-β-catenin) in SW480 and DLD1 cells treated with DZNep (5 μM), TSA (100 nM) or both.

B: Immunofluorescent images of DLD1 and SW480 cells treated with DZNep/TSA. β-catenin staining is red, nuclear staining is green (DRAQ5). Scale bars represent 10 μm.

C: Indicated colorectal cancer cell lines were treated as above; RNA was harvested and subjected to array analysis. Changes of expression of known Wnt/β-catenin target genes were shown using gene clustering program. Green represents down-regulated genes.

D: DLD1 and HT29 cells were treated as in A, and cell death was determined by PI staining and FACS analysis. The data represent Mean ± SD of three independent experiments.

E: HT29 cells were treated as in A, and Caspase 3 activity was measured by FACS analysis.

F: HT29 cells were treated as in A, followed by JC-1 staining and FACS analysis.




Figure 5. *DACT3* plays a role in inhibition of Wnt/ β -catenin signaling and apoptosis induction by DZNep/TSA

A: Two DLD1 stable clones expressing *DACT3* shRNA (*DACT3*-sh1 and *DACT3*-sh2) or DLD1 cells expressing a non-targeting control shRNA (NC) were treated with DZNep, TSA or both. *DACT3* and *actin* mRNA levels were determined by RT-PCR analysis; DVL2, active β -catenin and total β -actin protein levels were assessed by immunoblotting.

B: NC, *DACT3*-sh1 and *DACT3*-sh2 cells were treated as above and apoptosis was determined by PI staining and FACS analysis. The data represent Mean \pm SD of three independent experiments. **, $p < 0.01$.

C: SW480 cells transfected with *DACT3* SmartPool siRNA (*DACT3*-SP) and an independent *DACT3* siRNA (*DACT3*-2) were treated as in **A**. The data represent Mean \pm SD of three independent experiments. **, $p < 0.05$. Apoptosis, *DACT3* mRNA levels, DVL2, active β -catenin protein levels, and apoptosis were determined as previously.

D: SW480 cells transfected with *DACT1* siRNA were untreated or treated with DZNep/TSA, and harvested for mRNA and apoptosis analysis as above. The data represent Mean \pm SD of three independent experiments.




Figure 6. Effects of DACT3 overexpression on Dvl2 and β -catenin in colorectal cancer cells

A: Exogenously expressed DACT3 associates with Dvl2. SW480 cells were transiently transfected with the indicated Flag or HA-tagged expression constructs. DACT3 was immunoprecipitated with anti-Flag and the immunoprecipitates were probed with anti-HA antibody. Reciprocal coimmunoprecipitation between DACT3 and Dvl2 is shown on the lower panel.

B: Western blot analysis of HA-tagged Dvl2 protein levels in SW480 cells co-transfected with Flag-DACT3 or an empty vector.

C: Immunofluorescent images of SW480 cells transfected with Myc-tagged DACT1 or DACT3 expression construct for 72h. Myc-tagged DACT1 or DACT3 and β -catenin levels were detected by staining with anti-myc (green) and anti- β -catenin (red). Nuclei were stained by DRAQ5 (blue). Arrows indicate transfected cells expressing DACT3-myc. Scale bar represents 10 μ m.

D: Colony formation assay showing ectopic expression of DACT3 suppresses colon cell growth. DLD1 cells were transfected with a DACT3 expression vector or the empty vector, and selected for 12 days with Zeocin. The number of colonies relative to the control in triplicates is shown on the right (error bar: Mean \pm SD).